vascular endothelial growth factor

(redirected from Pazopanib)
Also found in: Medical, Encyclopedia.

vascular endothelial growth factor

n. Abbr. VEGF
Any of a family of signaling proteins that cause the proliferation of endothelial cells and the development of blood vessels. They are active during normal processes such as embryogenesis and also during certain pathological processes, such as the growth of malignant tumors. Several cancer drugs have been developed that inhibit the activity of these proteins or their cell receptors.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma (in combination with pazopanib) and non-Hodgkin's lymphoma (as a single agent).
Xynomic Pharmaceuticals announced that the independent ethics committees at three Chinese cancer hospitals have approved Xynomic's application to conduct pivotal Phase 3 trial using Xynomic's abexinostat, in combination with pazopanib, in patients with renal cell carcinoma.
Chez les patients atteints de sarcome des tissus mous avec metastases, "l'utilisation concomitante d'un medicament diminuant l'acidite gastrique et du pazopanib (un anticancereux commercialise sous la marque Votrient, reduit considerablement la survie sans progression de la maladie ainsi que la survie globale", conclut cette etude.
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cell Oncol (Dordr).
The two sets of drugs were sorafenib, sunitinib malate, and pazopanib hydrochloride for metastatic renal cell cancer (mRCC) and dasatinib, imatinib mesylate, and nilotinib hydrochloride monohydrate for chronic myeloid leukemia (CML).
The EVEREST trial focused at mammalian target of rapamycin (m-TOR) inhibitor (everolimus) and was not included due to lack of reported findings- Of five trials that focused on adjuvant TKI therapy, three published their findings: ASSURE (sorafenib and sunitinib), S-TRAC (sunitinib) and PROTECT (pazopanib) and represent the focus of this report and of the meta-analysis.
Between June 2002 and January 2016, 158 consecutive patients with mRCC treated with first-line vascular endothelial growth factor-targeted therapy (sorafenib, sunitinib, pazopanib, or axitinib) were retrospectively extracted from the prospectively collected kidney cancer database, in which all baseline demographics and clinical and laboratory data, including systemic inflammatory marker information, were prospectively collected.
Multitargeted kinase inhibitors, such as dabrafenib, vemurafenib, sorafenib, pazopanib, and ponatinib, are currently used for the treatment of cancer, which have later emerged as having antinecroptotic activity [59-61].
Pneumothorax has also been reported in association with other molecular-targeted drugs, including sunitinib for renal cell cancer [8], pazopanib for soft tissue sarcoma [9], and bevacizumab for colon cancer or breast cancer [10, 11].
He received high-dose palliative radiotherapy to the renal bed 40 Gray in 20 fractions followed by commencement of systemic treatment with dose-reduced pazopanib. The dose of pazopanib was reduced to 200 mg daily due to his poor ECOG performance status of 3 and ongoing renal dialysis.